Impact of Olaparib, Niraparib, Rucaparib therapies on Newly Diagnosed and Relapsed Ovarian Cancer -Systematic Review and Meta-Analysis.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2025-06-01 DOI:10.31557/APJCP.2025.26.6.1931

Seeta Devi, Ramesh Chandrababu

{"title":"Impact of Olaparib, Niraparib, Rucaparib therapies on Newly Diagnosed and Relapsed Ovarian Cancer -Systematic Review and Meta-Analysis.","authors":"Seeta Devi, Ramesh Chandrababu","doi":"10.31557/APJCP.2025.26.6.1931","DOIUrl":null,"url":null,"abstract":"Objective: This review aims to examine the effect of PARP inhibitors on PFS, OS, and adverse events in women with advanced ovarian cancer (OC).Methods: The PRISMA 2020 guidelines are followed while conducting this comprehensive review. Data from 17 randomized control trails (RCT) published between 2014 and June 2024 were included. These trials compared PARPi maintenance therapy to placebo women with newly diagnosed and recurrent advanced OC. The specific keywords were used to search relevant studies in databases including PubMed, SCOPUS, Cochrane library, and WoS. The main outcomes were the Progression free survival (PFS), overall survival (OS), or adverse events (AEs). The combined hazard ratios (HRs) and risk ratios (RRs) were determined, together with 95% confidence intervals (CIs). Each of the analyses were conducted using a model with random effects.Results: Despite high heterogeneity, the meta-analysis found that poly (ADP-ribose) polymerase inhibitors (PARPi) maintenance therapy ominously improved PFS compared to placebo, with a combined HR of 1.33 (95% CI: 1.10-1.61) in newly diagnosed cases and 0.88 (95% CI: 0.59-1.30) in relapsed cases. However, the OS improvement was not significantly substantial, with a collective HR of 1.06 (95% CI: 0.99-1.13). AEs are considerably higher in the PARPi groups, notably hematologic toxicities including anaemia, thrombocytopenia, and neutropenia. However, these adverse effects may be controlled with dosage modifications, and therapy was discontinued only in few cases.Conclusion: PARPi are an effective therapy in both newly discovered and relapsed. Although there is a modest rise in the frequency of severe adverse reactions, they are usually handled well.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 6","pages":"1931-1941"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.6.1931","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This review aims to examine the effect of PARP inhibitors on PFS, OS, and adverse events in women with advanced ovarian cancer (OC).

Methods: The PRISMA 2020 guidelines are followed while conducting this comprehensive review. Data from 17 randomized control trails (RCT) published between 2014 and June 2024 were included. These trials compared PARPi maintenance therapy to placebo women with newly diagnosed and recurrent advanced OC. The specific keywords were used to search relevant studies in databases including PubMed, SCOPUS, Cochrane library, and WoS. The main outcomes were the Progression free survival (PFS), overall survival (OS), or adverse events (AEs). The combined hazard ratios (HRs) and risk ratios (RRs) were determined, together with 95% confidence intervals (CIs). Each of the analyses were conducted using a model with random effects.

Results: Despite high heterogeneity, the meta-analysis found that poly (ADP-ribose) polymerase inhibitors (PARPi) maintenance therapy ominously improved PFS compared to placebo, with a combined HR of 1.33 (95% CI: 1.10-1.61) in newly diagnosed cases and 0.88 (95% CI: 0.59-1.30) in relapsed cases. However, the OS improvement was not significantly substantial, with a collective HR of 1.06 (95% CI: 0.99-1.13). AEs are considerably higher in the PARPi groups, notably hematologic toxicities including anaemia, thrombocytopenia, and neutropenia. However, these adverse effects may be controlled with dosage modifications, and therapy was discontinued only in few cases.

Conclusion: PARPi are an effective therapy in both newly discovered and relapsed. Although there is a modest rise in the frequency of severe adverse reactions, they are usually handled well.

查看原文本刊更多论文

奥拉帕尼、尼拉帕尼、鲁卡帕尼治疗对新诊断和复发卵巢癌的影响——系统评价和荟萃分析

目的：本综述旨在探讨PARP抑制剂对晚期卵巢癌（OC）妇女PFS、OS和不良事件的影响。方法：在进行全面审查时遵循PRISMA 2020指南。纳入了2014年至2024年6月期间发表的17项随机对照试验（RCT）的数据。这些试验比较了PARPi维持治疗和安慰剂对新诊断和复发的晚期OC妇女的影响。使用特定关键词在PubMed、SCOPUS、Cochrane library、WoS等数据库中检索相关研究。主要结局是无进展生存期（PFS）、总生存期（OS）或不良事件（ae）。确定合并危险比（hr）和风险比（rr），并确定95%可信区间（ci）。每个分析都是使用随机效应模型进行的。结果：尽管异质性很高，荟萃分析发现，与安慰剂相比，多聚（adp -核糖）聚合酶抑制剂（PARPi）维持治疗改善了PFS，新诊断病例的总风险比为1.33 (95% CI: 1.10-1.61)，复发病例的总风险比为0.88 （95% CI: 0.59-1.30）。然而，OS改善并不显著，总风险比为1.06 （95% CI: 0.99-1.13）。PARPi组的ae相当高，特别是血液毒性，包括贫血、血小板减少症和中性粒细胞减少症。然而，这些不良反应可以通过剂量调整来控制，只有少数病例需要停止治疗。结论：PARPi对新发和复发的肿瘤均有较好的治疗效果。虽然严重不良反应的频率略有上升，但通常处理得很好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.